Rubius Therapeutics Announces Dosing of First Patient in Phase I/II Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Rubius Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelia carcinoma and triple-negative breast cancer.